Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: January 27, 2023

Investigational Drug Information for GDC-0152


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for GDC-0152?

GDC-0152 is an investigational drug.

There have been 188 clinical trials for GDC-0152. The most recent clinical trial was a Phase 3 trial, which was initiated on October 9th 2020.

The most common disease conditions in clinical trials are Breast Neoplasms, Carcinoma, and Lymphoma. The leading clinical trial sponsors are Genentech, Inc., National Cancer Institute (NCI), and Hoffmann-La Roche.

There are sixty-five US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for GDC-0152
TitleSponsorPhase
Preoperative Window of Opportunity Study With Giredestrant (GDC-9545) or Tamoxifen in Premenopausal Women With ER[+]/HER2[-] & Ki67≥10% Early Breast CancerMedSIRPhase 2
A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic CoughGenentech, Inc.Phase 1/Phase 2
A Study to Assess the Safety and Pharmacokinetics of GDC-8264 in Combination With Standard of Care in Participants With Acute Graft-Versus-Host Disease (aGVHD)Genentech, Inc.Phase 1

See all GDC-0152 clinical trials

Clinical Trial Summary for GDC-0152

Top disease conditions for GDC-0152
Top clinical trial sponsors for GDC-0152

See all GDC-0152 clinical trials

US Patents for GDC-0152

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GDC-0152 See Plans and Pricing Peptidomimetic macrocycles as modulators of MCL-1 AILERON THERAPEUTICS, INC. (Cambridge, MA) See Plans and Pricing
GDC-0152 See Plans and Pricing Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitors AbbVie Inc. (North Chicago, IL) See Plans and Pricing
GDC-0152 See Plans and Pricing Bromodomain inhibitors AbbVie Inc. (North Chicago, IL) See Plans and Pricing
GDC-0152 See Plans and Pricing NAMPT and ROCK inhibitors AbbVie Inc. (North Chicago, IL) See Plans and Pricing
GDC-0152 See Plans and Pricing Bromodomain inhibitors AbbVie Inc. (North Chicago, IL) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GDC-0152

Drugname Country Document Number Estimated Expiration Related US Patent
GDC-0152 China CN108368161 2035-09-10 See Plans and Pricing
GDC-0152 European Patent Office EP3347372 2035-09-10 See Plans and Pricing
GDC-0152 Japan JP2018528217 2035-09-10 See Plans and Pricing
GDC-0152 World Intellectual Property Organization (WIPO) WO2017044633 2035-09-10 See Plans and Pricing
GDC-0152 Argentina AR095266 2033-03-12 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Express Scripts
Baxter
Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.